Corporate Profile
Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib, a highly selective inhibitor of the menin–KMT2A binding interaction, and axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Through its pipeline agents, the Company is determined to realize a future in which people with cancer live longer and better than ever before. Syndax corporate headquarters are in Waltham, MA.
Day High
Day Low
Volume
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Recent Events
Stifel 2024 Virtual Targeted Oncology Forum
04.17.24 / 11:00 AM EDT
Barclays Global Healthcare Conference
03.12.24 / 8:30 AM EDT
44th Annual TD Cowen Health Care Conference (Leukemia Panel Discussion)
03.04.24 / 12:50 PM EST